WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced the Company will be participating in two upcoming investor conferences.
Corindus Vascular Robotics’ management is scheduled to present at the Canaccord Genuity Medical Technologies & Diagnostics Forum in New York, NY on Thursday, November 9 at 9:00am ET.
Corindus Vascular Robotics’ management is also scheduled to present at the Stifel 2017 Healthcare Conference in New York, NY on Wednesday, November 15 at 11:00am ET.
Interested parties may access the audio webcast for both presentations on the “Investor Relations” section of the Company’s website at: www.corindus.com.
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.